6925 Guion Road
Indianapolis, IN 46268
T: (317) 347-2800
E: info@Exeleadbiopharma.com
Website: www.exeleadbiopharma.com


Exelead is a CDMO dedicated to the development and commercialization of therapeutics to treat life-threatening diseases for small populations. The company specializes in liposomal and PEGylated formulations for sterile drug products, offering rare dedication to the customer who needs a partner.

Exelead’s development capabilities can be utilized to improve drug delivery and drug product characterization. At their Indianapolis, Indiana manufacturing facility, the Exelead team produces proprietary parenteral pharmaceuticals for oncology and enzyme replacement treatment, as well as for the treatment of numerous infectious diseases.

Exelead staff is a balance of chemists, chemical engineers, microbiologists and pharmaceutical manufacturing experts. Senior Exelead management is comprised of seasoned executives from the pharmaceutical and biotechnology industries. The company is a wholly owned subsidiary of Essetifin S.p.A. (Rome, Italy) and is led by John Rigg, CEO.


End-to-End Solution

  • Method Development & Transfer
  • Process Development and Optimization
  • Technical Transfer
  • Clinical Manufacturing
  • Process Scale Up
  • Commercial Manufacturing
  • Project Management and CMC Support

Flexible Production

  • Liposomal Formulation
  • PEGylation
  • Aseptic Fill
  • Automated Inspection
  • Packaging
  • Quality Control
  • Sterility Assurance
  • Quality Assurance
  • Supply Chain